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ABSTRACT
PRAJA, a RING-H2 E3 ligase, is abundantly expressed in brain tissues such as 
the cerebellum and frontal cortex, amongst others, and more specifically in neural 
progenitor cells as well as in multiple cancers that include glioblastomas. However, the 
specific role that Praja plays in neural development and gliomas remains unclear. In 
this investigation, we performed bioinformatic analyses to examine Praja1 and Praja2 
expression across 29 cancer types, and observed raised levels of Praja1 and Praja2 in 
gliomas with an inverse relationship between Praja1 and apoptotic genes and Praja 
substrates such as Smad3. We analyzed the role of Praja in the developing brain 
through loss of function studies, using morpholinos targeting Praja1 in embryonic 
zebrafish, and observed that Praja1 is expressed prominently in regions enriched 
with neural precursor cell subtypes. Antisense Praja morpholinos resulted in multiple 
embryonic defects including delayed neural development likely through increased 
apoptosis. Further studies revealed high levels of Cdk1 with loss of Praja1 in TGF-β 
or insulin treated cells, supporting the link between Praja1 and cell cycle regulation. 
In summary, these studies underscore Praja’s role in mammalian brain development 
and Praja1 deregulation may lead to gliomas possibly through the regulation of cell 
cycle and/or apoptosis.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most 
common primary malignancy of the brain as it is highly 
infiltrative and has a poor prognosis among cancers. 
GBM constitutes 17% of all brain cancers, primary and 
metastatic, with median survival of 14.6 months and a two-
year survival rate of 30% [1]. With current therapeutics, 
improvement in patient survival is marginal, therefore 
identification of new targets remains urgent. E3 ligases 
have recently been identified as viable targets in cancer [2, 
3]. Yet to date, specific populations responsive to therapy 
have not been delineated for most cancer types including 
glioblastomas. We identified a RING E3 ligase, PRAJA 
that is highly expressed in brain tissues including the 
cerebellum, cerebral cortex, occipital pole, frontal lobe, 
amongst others [4]. Interestingly, Praja1 (PJA1) has been 
shown to be linked to human chromosome Xq12, between 
markers DXS983 and DXS1216, which is an area linked 
to X-linked mental retardation (MRX) [4]. Additionally, 
we have previously demonstrated that PJA1 is involved 
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in regulating tumor suppressors in the Transforming 
Growth Factor-β (TGF-β) signaling pathway [5-7]. In this 
investigation, to explore a potential role for PRAJA in 
tumorigenesis, we conducted a genomic analysis of Praja1 
(PJA1), Praja2 (PJA2) and Smad3 across 29 tumor types. 
One of the most striking observations was that the greatest 
amplitude in expression of PJA1 and PJA2 occurred in 
glioblastomas [8], and correlated with a concomitant and 
significant decrease in expression levels of Smad3, which 
we have identified as a PJA1 substrate [6, 7], and as a key 
receptor that regulates TGF-β signaling molecules [9, 10]. 
A precise sequence of genetic, biochemical, physical 
and environmental factors lead to the development 
of accurately placed nerve cells in the cortex, with its 
dendrites, synapses and axons in a network where each 
neuron functions as a part of the symphony that makes 
up the brain [11]. Ubiquitination and apoptosis are 
major mechanisms that are active amongst neuronal cell 
precursors and neurons to modulate the population and 
connectivity of the cerebral cortical neurons. For instance, 
E3 ligases play a role by the degradation of the pro-
apoptotic p53 and a few anti-apoptotic factors. Another 
example is the degradation of Myc protein by the E3 
ligase Huwe1, which allows expression of neurogenic 
markers (Neurogenin, N-Cadherin and MAP2) normally 
suppressed by Myc [12]. Here we report the expression of 
PJA1 E3 ligase in embryonic brain development as well 
as in TGF-β deficient Sptbn-/- mutant mice. Loss of PJA1 
in a zebrafish model leads to delayed neural development, 
apoptosis, as well as loss of dorsalization. Further kinases 
analysis revealed the association of PJA1 with cyclin-
dependent kinase 1 (Cdk1, cdc2) activation [13, 14], 
indicating a functional pathway in cell cycle, apoptosis as 
well as neural malignancies such as gliomas.
RESULTS
Bioinformatic analyses revealed increased levels 
of PJA1 and PJA2 in brain malignancies
PJA1 and PJA2 share more than 80% sequence 
identity of the RING finger domain at the C-terminal. To 
Figure 1: Bioinformatic analyses of PJA1, PJA2 and Smad3 genetic alterations in brain tumors from the databases of 
The Cancer Genome Atlas. A. PJA1 and PJA2 RNA expressions shown across 29 cancer types in TCGA databases. RNA expression 
is shown to be relatively higher in gliomas and glioblastoma multiforme. B. Cancer histogram analysis of genetic alterations of PJA1 and 
PJA2 in 36 cancer types in TCGA databases. C. Analyses of PJA1, PJA2, and Smad3 expression in the TCGA merged cohort of LGG 
and GBM dataset TCGA Brain Lower Grade Glioma (LGG) dataset (n = 794). D. Analyses of PJA1, PJA2, and Smad3 genetic alterations 
in the TCGA LGG dataset (n = 530). Genetic alterations of PJA1 frequently co-occur with Smad3 alterations (p = 0.001) whereas PJA2 
alterations are mutually exclusive with Smad3 alterations (p = 0.029). E. Association of PJA1 with Smad3 and Sptbn1 was examined by 
co-immunoprecipitation with anti-PJA or anti-SPTBN1 in cells transfected with indicated plasmids and the binding of PJA1 with Smad3 
and SPTBN1 was determined by anti-V5. 
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better understand their roles in brain development and 
malignancies, we performed bioinformatic analyses of 
the expression of PJA1 and PJA2 across 29 cancers in 
the TCGA databases and found that both PJA1 and PJA2 
are highly expressed in brain malignancies including 
Glioblastoma (GBM) and Gliomas (Figure 1A) [8]. The 
same results were observed in the TCGA adrenocortical 
carcinoma study and an advanced prostate cancer study 
[15] (Supplementary Figure 1). We further analyzed 
genetic alterations of PJA1 and PJA2 that include copy 
number (CPN) gain, amplification, shallow deletion, deep 
deletion and mutations in 36 different cancer types. CPN 
gain and amplification are the most common alterations of 
these genes across all cancer types analyzed (Figure 1B), 
suggesting potential oncogenic roles of PJA in cancers. In 
a TCGA study with merged cohort of Low Grade Glioma 
(LGG) and GBM [8], PJA1, PJA2 Smad3 and altered in 
9%, 4% and 14% of samples, respectively (Figure 1C). 
Similarly, we observed increased expression of PJA1 and 
PJA2 in 20% and 10%, respectively, of the 530 samples 
from 516 sequenced patients in a TCGA study on LGG 
(Figure 1D). While CPN gain or amplification is frequently 
observed in PJA1 and PJA2, Smad3 is more frequently 
downregulated or deleted (Figure 1C-1D). Interestingly, 
genetic alterations of PJA1 but not PJA2 frequently co-
occur with Smad3 alterations, which is consistent with 
our previous findings that PJA1 directly binds to TGF-β 
signaling components, Smad3 and its adaptor SPTBN1 
(Figure 1E) [7]. 
PJA1 is expressed in brain regions enriched with 
neuronal precursor cells
Given that PJA1 is highly expressed in brain 
malignancies, we then examined PJA1 expression in 
brain tissues. Northern blot analysis of PJA1 mRNA 
demonstrates a 2.7 kb transcript in human brain tissues and 
is found to be more abundantly expressed in the cerebral 
cortex, occipital lobe, frontal lobe, cerebellum and caudate 
nucleus. Relatively low abundance of the PJA1 transcript 
is seen in the brainstem structures, such as the medulla, 
spinal cord, corpus callosum and substantia nigra (Figure 
Figure 2: PJA1 expression in brain. A. Northern blot analysis of PJA1 expression in human brain tissues. Cerebral cortex, occipital, 
frontal lobes and caudate nucleus demonstrate prominent mRNA for PJA1. B. Immunoperoxidase labeling of PJA1 in E12 mouse embryo 
forebrain marginal zone (MZ) (i) and mantle zone (ii). The left panel (i) shows Cajal-Retzius cells of the marginal layer labeled (arrows) 
while the right panel (ii) shows fibrillary label extending from cells in the mantle zone. C. Immunoperoxidase labeling of PJA1 in E12 
mouse embryo midbrain (i) and cerebellum (ii). PJA1 is expressed in the SVZ cells and in developing midbrain nuclei (arrows). D. PJA1 
expression compared in E12 forebrain of wild type (i-ii) and mutant Sptbn1-/- mice (iii, iv). Left panels are (i, iii) at 20X magnification; right 
panels (ii, iv) are at 40X magnification. PJA1 is expressed in SVZ cells and appears to be more widely distributed in embryonic brain of 
mutant Sptbn1-/- mice. E. Immuno-histochemical analysis of H & E staining of mouse embryos reveals the fore brain development defect 
in mutant Sptbn1-/- mice.
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2A). Additional immunohistochemistry (IHC) staining of 
PJA1 in normal brain revealed that PJA1 is expressed in 
the hindbrain, midbrain, forebrain, cerebellum, and basal 
ganglia of E12 and E15 (12 and 15 days post-coitum) 
embryonic mice (Figure 2B-2C). Earlier, day 11.5 embryos 
were found to express PJA1, in the Subventricular Zone 
(SVZ) cells. PJA1 label is observed in cells that are 
identified as Cajal-Retzius cells by morphology and 
location [16], in the outer layer (marginal zone) of the E12 
developing cortex in mouse embryo brain (Figure 2B, i). 
PJA1 label is also demonstrated in the cells of the SVZ in 
E12 forebrain cortex (Figure 2C ii). In both cell types, the 
label appears perinuclear and polarized. In the developing 
forebrain cortex, PJA1 label also appears in fibrillar form 
extending from cells with larger nuclei (Figure 2B ii). 
This fibrillary appearance is also observed with the TGF-β 
adaptor, SPTBN1 labels at the same embryonic stage of 
mouse brain development. In the midbrain, cerebellum, 
and hindbrain, PJA1 is expressed in the cytoplasm of 
scattered cells among the developing midbrain and 
brainstem nuclear groups (Figure 2C i). However, SVZ 
cells continue to express PJA1 (Figure 2C ii). 
Consistently, PJA1 IHC in different areas of E12 
brain demonstrates that PJA1 is normally expressed in the 
SVZ that is enriched with neuronal precursor cells [17] and 
the collection of hindbrain nuclei in E12 embryonic brain 
of wild type mouse embryo (Figure 1D i, ii). Interestingly, 
in contrast to that of wild type mice, PJA1 expression is 
more widely expressed in the developing brain of TGF-β 
deficient (Sptbn1-/-) mutant mice. Additionally, PJA1 
expression appears to be strongly diffused in Sptbn1-/- 
mutant mice compared with that in wild type SVZ cells 
(Figure 1D iii, iv). It is noteworthy that the mutant embryo 
brain exhibits multiple fore brain developmental defect 
including abnormal brain vesicles, further suggesting 
an important role of PJA1 in normal brain development 
(Figure 1E) [10, 18].
Loss of PJA1 leads to developmental defect 
in zebrafish embryonic brain with increased 
apoptosis
We also detected normal PJA1 expression in 
zebrafish embryo (Figure 3A) using whole mount in situ 
hybridization. PJA1 is expressed in the yolk sac and is 
evenly and strongly expressed along the entire length of 
the embryo, with a steep ventral-dorsal gradient such that 
high ventral expression abruptly drops to undetectable 
levels in the dorsal-most 20-30% of the embryo. By 28 
hours post-fertilization (hpf), the PJA1 expression pattern 
becomes more refined and restricted to specific tissues. In 
the brain, PJA1 is strongly expressed throughout the basal 
plate, while expression in the alar plate is predominantly 
restricted to the ventricular zones. In addition, PJA1 is 
expressed in the head mesenchyme, intestinal and vascular 
Figure 3: Apoptosis dramatically increases in zebrafish embryos upon PJA1 knockdown. A. PJA1 mRNA expression was 
determined by whole-mount in situ hybridization in developing embryos. PJA1 mRNA is expressed in the yolk and ventral side of the 
embryo at the 13 somite stage (i) and in intestinal and vascular tissues at 28 hour post-fertilization (hpf) (ii). B. Developmental defects were 
observed in zebrafish embryos injected with 4ng or 8ng of antisense PJA1 morpholino oligonucleotides (MO) but not in embryos injected 
with same dose of control MO. C. Apoptosis was visualized by acridine orange staining in live embryos, where apoptotic cells are indicated 
by green fluorescence. Compared to that of the control MO injected embryos at 24 hpf. D. injection of PJA1 MOs severely disrupted 
embryogenesis (v) and resulted in high levels of apoptosis (vi). Red squares indicate the embryonic brain of zebrafish.
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structures of the trunk and tail, and mesendodermal 
tissues near the yolk sac (Figure 3A), indicating that 
PJA1 may play a particularly important role in GI organ 
development.
To test our hypothesis that PJA1 is required for 
normal brain development, translation-blocking antisense 
PJA1 Morpholino oligonucleotides (MO) were injected 
into single-cell stage zebrafish embryos to knock down 
PJA1 that is normally expressed in zebrafish embryos 
(Figure 3A). As we expected, morpholino-mediated 
PJA1 knockdown results in multiple developmental 
defects throughout the embryo (Figure 3B) including 
reduced brain development, shortened and deformed tail, 
abnormal notochord, and loss of the chevron shape of the 
somites. The overall appearance of the PJA1 MO injected 
embryos (Praja1 morphants), in comparison to control 
MO injected embryos, is that they have smaller head size 
with curved bodies and tails (Figure 3B-3C). Further, we 
found increased apoptosis visualized by acridine orange 
staining throughout the somitogenesis period in PJA1 
MO injected embryos relative to control MO injected 
embryos. By 24 hpf, when somitogenesis is complete and 
most organ primordia have formed, apoptosis remains 
high, specifically in the head (Figure 3C iv, vi); by 36 hpf, 
apoptosis in PJA1 morphants starts to level off; and by 48 
hpf is only slightly higher than that in control embryos. 
These studies indicate that PJA1 is important for inhibiting 
apoptosis during zebrafish embryogenesis. 
PJA1 protects cells from apoptosis
To further examine the potential mechanism for 
the developmental defects caused by PJA1 inhibition 
and determine the role of PJA1 in cellular apoptosis, we 
introduced RING domain-deleted mutant PJA1 (ΔRING 
mut) in cells. This mutant was identified as a loss-of-
function mutant by our group in the regulation of TGF-β 
signaling through Smad3 and its adaptor, SPTBN1 [7, 
19, 20]. Through Annexin V staining, we found that 
expression of PJA1 mutant in cells results in three-fold 
increase of apoptosis (Figure 4A). In addition, knockdown 
of PJA1 by shRNA in HepG2 cells leads to increased cell 
apoptosis as determined by increased PARP expression 
as well as increased Caspase 3 and cleavage of Caspase3 
Figure 4: PJA1 defects lead to increased cell apoptosis. A. Apoptotic response to Cisplatin of the Huh7 cells that express a RING 
domain-deleted PJA1 mutant. The expression of the inactive PJA1 mutant (ΔRING mut) causes more than a three-fold increase in the 
percentage of apoptotic cells. B. Apoptotic response of HepG2 cells with reduced PJA1 expression after treatment with Sorafenib. PJA1 
knockdown demonstrated that Caspase3 and PARP cleavage were significantly elevated compared to control with a dose-dependent pattern. 
C. The percentage of apoptotic cells is consequently higher in PJA1 knockdown and Sorafenib treatment. D. Negative Pearson’s correlation 
between PJA1 and apoptotic genes in TCGA LGG dataset.
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(Figure 4B). To examine whether kinases are required 
for apoptosis induced by PJA1 defect, we treated cell 
with Sorafenib, a tyrosine kinase inhibitor. Interestingly, 
Sorafenib synergizes with PJA1 knockdown to increase 
cell apoptosis in a dose-dependent manner (Figure 4B-
4C). Consistently, analysis of co-expression of genes with 
PJA1 revealed a negative Pearson’s correlation between 
PJA1 and several apoptotic genes, including Bax and Bak 
as well as caspases 6, 8, 10, 1, 4 and 7 in LGG (Figure 
4D). All these data strongly support the anti-apoptotic 
effect of PJA1. 
PJA1 is associated with CDK1 activation
To further explore the mechanism underlying PJA1-
mediated brain development, we performed KinetworksTM 
phosphor-site broad coverage pathway screen in cells 
transfected with either wild type PJA1 or PJA1 ΔRING 
mut, a loss-of-function mutant [7]. Profiles of activated 
kinases, induced by either TGF-β or insulin treatment, 
were examined through band visualization via ECL and 
quantification (Figure 5A-5D). We observed consistently a 
two-fold induction of Cdk1 phosphorylation at T14/Y15 in 
both TGF-β and insulin treated cells transfected with PJA 
mut compared with cells transfected with PJA wild type 
(Figure 5, Supplementary Tables 1-4), indicating that Cdk1 
activation is negatively regulated by PJA1. Our study is 
in line with previous findings showed that aberrant Cdk1 
activation has been associated with neuronal cell apoptosis 
and Cdk1 is critical to brain development [13, 14, 21-23]. 
In addition to Cdk1 activation, insulin activating through 
insulin receptors induces activation of MEK/ERK and 
Akt signaling pathway in cells expressing PJA1 mutant, 
suggesting a negative regulation of these pathways by 
PJA1 as well. 
DISCUSSION
In this study, we explored the role of praja1 (PJA1) 
in brain development and found that PJA1 protects cells 
from apoptosis and is required for the normal embryonic 
development. In addition, loss of PJA1 leads to hyper-
activation of Cdk1 and thereby induces cell apoptosis 
during early embryogenesis possibly through cell cycle 
mitosis stress as Cdk1 is known to interact with cylin 
B1 to control the progression of cell cycle from G2- to 
M-phase. Aberrant Cdk1 activation has been associated 
Figure 5: Elevated Cdk1 activity is associated with loss of PJA1. A. Increased Cdk1 phosphorylation in cells transfected with 
PJA mutant. Protein phosphorylation visualized by ECL show increased phosphorylation activity in Cdk1 (Lane 7) in TGF-β treated 
cells transfected with PJA1 mutant (ΔRING mut) (right) compared to that in cells transfected with wild type PJA1 setting (left). The 
quantification results of bands were showed in the top table. B. Bar graph shows the quantification of the phosphorylation of each kinase 
and their respective sites as indicated in A. C. Increased phosphorylation activity in Cdk1 (Lane 7) in insulin treated cells transfected with 
PJA1 mutant (ΔRING mut) (right) compared to cells transfected with wild type PJA1 setting (left). The quantification results of bands were 
shown in the top table. D. Bar graph shows the quantification of the phosphorylation of each kinase and their respective sites as indicated 
in C. 
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with cell apoptosis [13, 14, 21-24]. 
Our integrated genomic analyses of LGG and 
GBM indicate a potential new role for PJA1 in gliomas, 
potentially through its preciously demonstrated 
ubiquitination of the Smad3- likely reflecting the TGF-β 
tumor suppressor role in this cancer [5-7, 9, 10, 18]. 
Interestingly, although we observed PJA2 mutations in 
brain cancer [8], we found no mutations in PJA1, only 
alterations leading to raised PJA1 expression. Further 
insight into PJA1 was obtained by examining its co-
expression with apoptotic genes. Pearson’s correlation 
analysis revealed a negative moderate relationship 
between PJA1 and these apoptotic genes, which suggest 
an negative anti-apoptotic role of PJA1. Indeed, PJA1 
knockdown leads to high levels of apoptosis. This pro-
survival, anti-apoptotic role for PJA1 lends further support 
to the notion that it may be function as an oncogene. 
The study suggests important functions for PJA1 
in the neural development as well. The appearance of 
PJA1 label in the region enriched with neural progenitors 
(SVZ cells) without labeling radial glial cells and other 
progenitor cells, characterizes a subset of progenitor cells 
by phenotype. Cajal Retzius cells and subventricular zone 
cells are predominant early neural progenitor cells of 
embryonic brain. Usually also confirmed by double label 
with ‘Reelin’ [25]- Cajal Retzius cells are located in the 
outer zone of the developing cortex, and have been shown 
to differentiate into neuronal cell phenotype [26]. SVZ 
cells on the other hand are nestin [27] positive, musashi-1 
[28] positive, and give rise to radial glial cells that in turn 
populate the embryonic forebrain cortex with neuroblasts. 
Loss of PJA1 expression in zebrafish led to 
apoptosis, resulting in delayed neural development. The 
upregulation of Cdk1 in loss of PJA1 function suggests 
a key role of loss of PJA1 expression in the irregularities 
of Cdk1/cyclin B mitotic cascade that instigates hyper-
phosphorylation of neuronal proteins and neuronal 
apoptosis. Interestingly, previous research has marked 
that Cdk1/cyclin B overexpression in gliomas, marking 
it as a potential oncogene and highlighting the various 
apoptotic roles that Cdk1/cyclin B plays contingent upon 
Praja expression [13, 14]. 
PJA1’s role in neural development and gliogenesis 
can be understood through its structural and functional 
homolog PJA2 and its role as an A-kinase-anchoring 
protein (AKAP), which anchors protein kinase A1 (PKA) 
to specific intracellular sites and is involved in protein 
sorting at axosomatic synapses [29]. PKA and cAMP also 
serve roles in axon formation as impeding PKA anchored 
to AKAPs increased cAMP gradient in neurons which led 
to enhanced axon elongation [30]. PJA1 appears to play a 
multifunctional role in neuronal development. The MAGE 
(melanoma antigen) member NRAGE (neurotrophin 
receptor associated MAGE famohomologue), also 
known as Dlxin-1 in mouse and MAGE-D1 in human 
[31], is directly targeted by PJA1 for ubiquitination and 
subsequent degradation [32]. NRAGE deletion impedes 
BMP regulated neural developmental apoptosis of 
sympathetic neurons [33]. In addition, NRAGE has also 
been found to inhibits several AKAPs in conjunction 
with p75 neurotrophin receptor (p75NTR) [34]. A recent 
study found that PJA2 induces ubiquitin/proteasomal 
degradation of Mob1 (Mps one binder 1), a kinase 
regulator of the Hippo cascade, promoting glioblastoma 
formation [35]. Collectively, our studies demonstrate 
an important role for Praja in neural development, and 
gliomas, providing a basis for future investigations into 
targeting Praja in gliomas, that are lethal cancers.
MATERIALS AND METHODS
Bioinformatics analysis
The Cancer Genome Atlas (TCGA) database from 
cBioportal was utilized to examine transcriptomic and 
genomic alterations of Praja1 (PJA1), Praja2 (PJA2), and 
Smad3 (SMAD3) (http://www.cbioportal.org/). Genomic 
profiles were chosen based on our studies of interest 
including TCGA Brain Lower Grade Glioma (LGG), 
consisting of 530 samples from 516 patients, and TCGA 
Merged cohort of LGG and Glioblastoma Multiforme 
(GBM), consisting of 794 samples. Mutations, putative 
copy number alterations from GISTIC, mRNA expression 
z-scores (RNA Seq V2 RSem; z-score threshold ± 2), 
and protein expression z-scores (z-score threshold ± 2) 
were chosen out of the profiles for TCGA Lower Grade 
Glioma and TCGA merged cohort of LGG and GBM. 
PJA1 and PJA2 expression were first analyzed across 
all cancer types. Oncoquery language was utilized for 
the selection of samples with gain of function (GAIN), 
amplification (AMP), mRNA upregulation (EXP > = 1.5), 
or mutations in PJA1 or PJA2 (MUT), as well as deletion 
or loss (HETLOSS, HOMEDEL), mRNA downregulation 
(EXP < = -1.5), or mutation in Smad3 when observing 
TCGA Lower Grade Glioma. Following the completion 
and submission of the outlined query, the oncoprint, 
mutations, mutual exclusivities, and mRNA coexpression 
tabs were chosen and their results were individually 
recorded. Specifically, when examining the oncoprint 
results, the percentage of patient samples with alterations 
in the queried genes and whether those various samples 
increased expression of the genes (i.e. amplification, 
gain, or mRNA upregulation) or decreased expression 
(i.e. deletion, loss, or mRNA downregulation) was noted 
and observed. Subsequently, we attempted to identify 
mutations in PJA1 and PJA2 in these malignancies, 
thereby juxtaposing the results and structures of the 
two genes. While examining the mutual exclusivity or 
co-expression of PJA1, PJA2, and Smad3 in the TCGA 
Lower Grade Glioma dataset, the statistical significance of 
these relationships was noted. Additionally, while utilizing 
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mRNA co- expression from the TCGA Lower Grade 
Glioma dataset, Pearson’s correlation between PJA1 and 
genes (Caspases 1, 4, 7, 6, 8, 10) implicated in apoptosis 
were noted. 
Northern blot analysis
Northern blots with 2 μg poly-A(+) mRNA 
from human brain (Clontech, USA) were probed 
with 32P-labeled Praja Clone CH7 [5] insert antisense 
strand using ExpressHyb hybridization solution 
(Clontech, USA) at 68oC. They were washed according 
to the manufacturer’s instructions and subjected to 
autoradiography. A 32P-labeled β-actin probe supplied 
with the Northern blots was used as a control to confirm 
that normalized RNA levels were present in each lane 
(Clontech).
Embryonic tissue preparation
129SvEv/Black Swiss Mice were used following 
an institutionally approved animal protocol in accordance 
with the requirements and recommendations of the NIH 
“Guide for the Care and Use of Laboratory Animals.” The 
age of the embryos was determined by post-appearance of 
the vaginal plug (day 0). Noon of this day was considered 
0.5 days of gestation post-coitus (p.c). The embryos 
were dissected at transitional times between days of 9.5 
and 14.5 p.c. The identification and isolation of embryos 
were carried out under an operative microscope. The 
specimens were fixed in FEA fixative (4% formaldehyde, 
85% ethanol and 5% glacial acetic acid) and embedded 
in paraffin [36]. The sections, 8-15 μM thick, were cut in 
the longitudinal or transverse planes using a microtome 
(Reichert-Jung, USA). 
Immunohistochemical staining
An indirect immunoperoxidase procedure was 
used for immunohistochemical localization of Sptbn1 
and PJA1 protein in brain tissues of mouse embryos. 
Antibody to a peptide corresponding to amino acids 145-
149 (CLRRKYRSREQPQS) of PJA1 was produced in 
rabbit, and used to detect Praja by immunohistochemical 
labeling [5]. For β2SP, the primary antibody used was 
rabbit antimouse EL-1 (against N-terminal aminoacids 
2-14, ELQRTSSVSGPLS) as described previously [7, 
19, 20]. Sections (8 μM) were treated with xylene to 
remove paraffin, and the tissue was dehydrated by placing 
it stepwise into graded higher concentrated alcohol and 
rinsed in 1x phosphate-buffered saline (PBS). Endogenous 
peroxidase was quenched using 3% hydrogen peroxide 
(Sigma). Non-specific binding sites were blocked with 
1x PBS containing 5% goat serum and 1 mg/ml bovine 
serum albumin (BSA). The sections were incubated 
overnight at 4°C in humidor with primary antibody diluted 
to 2.5-5 μg/ml in 1x PBS containing 1 mg/ml BSA and 
0.05% Triton X-100. All subsequent steps were done at 
room temperature, including four 5-min rinses with 1x 
PBS containing 1% goat serum after each successive 
step. Sections were incubated with peroxidase-conjugated 
goat anti-rabbit antibody (Jackson Immunoresearch 
Laboratories, West Grove, PA) that was diluted in 0.05M 
PBS in 1% serum for 30 min. After rinses, 200-500 μl 
of the insoluble peroxidase substrate DAB (Sigma Fast) 
was added to cover the entire tissue on the slide. Color 
development was monitored under the microscope, 
and then slides were rinsed for 2 min in distilled water. 
Counterstaining was then performed with Harris’s 
hematoxylin solution (Sigma) (modified) for 1 min, 
followed by a rinse in distilled water for 5 min. Sections 
were dehydrated by passage through graded alcohol 
concentrations and xylene. The coverslips were mounted 
using DPX (Fluka Labs).
Morpholino injection in zebrafish embryos
Morpholinos were synthesized and purchased 
from Gene Tools (http://www.gene-tools.com/). A stock 
solution of 10μg/μl was prepared by dissolving the 
lyophilized powder in twice-distilled water. The stock 
solution was diluted to a working concentration of 2μg/μl 
in 1× Danieau’s solution. Freshly laid zebrafish embryos 
were collected and placed into embryo culture medium 
and transferred onto an agarose platform. 4ng or 8ng of 
morpholinos targeting PJA1 or control mopholinos was 
injected in the yolk of embryos. Microinjection was 
performed using a Nanoject injector II. 
Praja function and loss of function proteomics
Cultured cells transfected with wild type PJA1 
or PJA1 ΔRING mut were treated with either TGF-β 
(100pm) for 30min or insulin (100ng/ml) for 30min 
after 5h starvation. Then cells were lysed with RIPA 
lysis buffer supplemented with phosphatase and protease 
inhibitors. Protein concentrations were determined by 
Bio-Rad Bradford assay prior KinetworksTM phosphor-site 
broad coverage pathway screen (Kinexus Bioinformatics 
Corporation). Protein phosphorylation activities were 
analyzed, including the combination of both analytical 
techniques such as immunoblotting, protein visualization 
through enhanced chemiluminescence (ECL), and gel 
electrophoresis, as well as assorted methodologies. Thus, 
the target kinases including Src, Erk1, Erk2, Jun, Cdc2, 
Akt1, FAK, MAPK, MEK1, Rb, ERK2/Hu, and PKR were 
determined by the KCPS-1.0 screen. Through the process, 
an adequate reading of the quantities was observed over a 
2000-fold linear range. 
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